Following the demonstration by Rygaard and Povlsen (1969) that human tumours could be grown in congenitally athymic mice and the subsequent use of thymectomised, whole-body irradiated mice suitable for tumour heterotransplantation (Castro, 1972) , large numbers of serially transplantable human tumour xenograft lines have been established (Shimosato et al., 1976 Giovanella et al., 1978) . In spite of extensive data on the establishment, biological characteristics and drug response of these xenografts, their clinical relevance is not yet clear. There is an increasing body of evidence to suggest that xenografts of a particular tumour type (e.g. chorion carcinoma, Burkitt's lymphoma) are sensitive to the chemotherapeutic agents active clinically in these diseases (Povlsen & Rygaard, 1974; Hayahashi et al., 1978) . There is also evidence that a xenograft line retains the same spectrum of chemosensitivity as the individual patient from whom the original tumour was obtained (Shorthouse et al., 1980; Nowak et al., 1978) . One potential use of this system is the testing of an individual patient's tumour for response to a variety of cytotoxic drugs (Povlsen, 1978) .
In a review article by Double in (1975) it was suggested that use of xenografts in chemotherapy testing might be as a secondary screen for new agents rather than as a test for individual patient's tumours, but it seemed possible that improvements in technique might have invalidated this prediction. We therefore analysed our data with regard to five tumour types extensively studied at our laboratories to assess whether xenografts could be used for individual patient drug sensitivity testing.
Throughout this study, immunosuppressed CBA/lac mice were used for tumour implantation. The immunosuppression was effected by thymectomy at 4 weeks of age, followed by 9 Gy whole-body irradiation 4-8 weeks later. (usually 10-20) . Several cubes were examined histologically.
Drug testing was carried out using a control group of 5-10 tumour bearing mice, and groups of 5-10 mice with tumours for each drug to be tested.
Testing was performed on the earliest passage at which sufficient tumour bearing mice could be produced.
All patients were followed by personal interview and examination for at least one year, or until the patient died. Further details of implantation technique, histological methods and chemosensitivity testing have been published elsewhere (Bailey et al., 1980b; Raghaven et al., 1980a Raghaven et al., , 1980b Selby et al., 1979 Selby et al., , 1980 Jones et al., in preparation; Shorthouse et al., 1980) . Specimens from 339 patients were implanted and shown to al., 1976; Povlsen, 1978; Giovanella et al., 1978) . Work undertaken at our institute has shown no difference in take rates between the immunosuppressed mouse used in these studies and the congenitally athymic mouse often used as an alternative Bailey et al., 1980 ). Considerable effort has been directed towards raising the take rate but no dramatic increase in establishing serially transplantable human tumour lines has occurred to suggest that the overall take rate of 31 % can be improved.
We have defined a "Usable take" for the purposes of this paper as being a xenograft line established from a human tumour and maintaining histological and karyotypic characteristics of that tumour in serial passage in immunosuppressed mice, which, by virtue of passage, could be implanted into sufficient mice to allow chemotherapy trials to be undertaken yielding results within the lifespan of the donor patient.
We have therefore excluded from our analysis patients whose disease at the time of implantation to the mice was so advanced as to render any prospect of their survival until xenograft testing could be performed unlikely. Even so, only 11% of the patients whose tumours were implanted had xenograft lines established which could have yielded useful drug sensitivity data before their death. It may be that the reason so few patients could have benefited from drug testing is that patients with less aggresive tumours who survived long enough for testing to have been possible had a low xenograft take rate. 
